Literature DB >> 2062772

Biochemical effects of urapidil on red cell membrane ion transport systems in a population of elderly essential hypertensives.

R Antonicelli1, E Balducci, G Lipponi, C Lucantoni, R Gaetti, E Paciaroni.   

Abstract

The aim of our work was to verify the effect of urapidil on membrane ion transport systems. This was a randomized, double-blind, cross-over study which evaluated the clinical and biochemical effects of urapidil (30 mg twice daily in comparison with placebo) in a group of 10 elderly hypertensive patients (3 male, 7 female ranging from 68 to 90 years, mean age 79.2 +/- 7.6 years). For the evaluation in fresh erythrocytes of principal ion transport systems (cotransport Na+/K+, countertransport Na+/Li+, Na+/K+ ATPase pump. intracellular Na+ and K+) we used the nystatin technique. We found that urapidil activated the red cell membrane ions cotransport system (basal values: 83.7 +/- 50.3 mumol Na+ RBC 1-1.h-1, after 1 month of urapidil therapy: 181.5 +/- 89.3 mumol Na+ RBC 1-1.h-1) (P less than 0.01), without significant changes in the other biochemical parameters evaluated. Our data suggest that one of the mechanisms of the urapidil antihypertensive effect could involve an increase in the membrane sodium cotransport system.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2062772      PMCID: PMC2399009          DOI: 10.1136/pgmj.67.785.252

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  19 in total

1.  Renal haemodynamic and neurohumoral responses to urapidil in hypertensive man.

Authors:  P W de Leeuw; P N van Es; H A de Bruyn; W H Birkenhäger
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 2.  Effects of alpha-adrenoceptor blockers on renal function and blood pressure adjustment in human hypertension.

Authors:  G Leonetti
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 3.  Antihypertensive drugs interacting with alpha- and beta-adrenoceptors. A review of basic pharmacology.

Authors:  P A van Zwieten
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 4.  Urapidil in the treatment of hypertension.

Authors:  C Rosendorff
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 5.  Human pharmacology of urapidil.

Authors:  A M Shepherd
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 6.  Urapidil-induced hemodynamic changes in humans.

Authors:  E Bielen; R Fagard; J Staessen; P Lijnen; R Van Hoof; A Amery
Journal:  Am J Cardiol       Date:  1989-08-15       Impact factor: 2.778

7.  [Na+, K+, Cl-]-cotransport function and dysfunction in different forms of primary hypertension.

Authors:  M N Saitta; P A Hannaert; C Rosati; A S Diaz; N Senn; R P Garay
Journal:  Am J Hypertens       Date:  1988-07       Impact factor: 2.689

Review 8.  New alpha 1-adrenergic receptor antagonists for the treatment of hypertension: role of vascular alpha receptors in the control of peripheral resistance.

Authors:  L X Cubeddu
Journal:  Am Heart J       Date:  1988-07       Impact factor: 4.749

9.  Efficacy of once-daily urapidil treatment in mild or moderate essential hypertension assessed by ambulatory 24-hour blood pressure monitoring.

Authors:  B Trimarco; G Rosiello; P Feldhaus; V W Steinijans; F Vecchione; A Cuocolo; G Lembo; M Volpe
Journal:  Drugs       Date:  1988       Impact factor: 9.546

10.  Pharmacokinetics and pharmacodynamics of urapidil in severe hypertension.

Authors:  M B Bottorff; T J Hoon; J H Rodman; P A Gerlach; K B Ramanathan
Journal:  J Clin Pharmacol       Date:  1988-05       Impact factor: 3.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.